Bone marrow CD3+CD56+ regulatory T lymphocytes (TR3−56 cells) are inversely associated with activation and expansion of bone marrow cytotoxic T cells in IPSS‐R very‐low/low risk MDS patients. (14th July 2022)

• Record Type: Journal Article
• Authors: Leone, Stefania; Rubino, Valentina; Palatucci, Anna Teresa; Giovazzino, Angela; Carriero, Flavia; Cerciello, Giuseppe; Pane, Fabrizio; Ruggiero, Giuseppina; Terrazzano, Giuseppe
• Is Part Of: European journal of haematology. Volume 109:Number 4(2022)
• Page Start: 398
• Page End: 405
• Publication Date: 2022-07-14
• Subjects: bone marrow -- cytotoxic T‐lymphocytes -- myelodysplastic syndrome -- T lymphocytes regulatory; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.13822
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Background: Emergence of dysplastic haematopoietic precursor/s, cytopenia and variable leukaemia risk characterise myelodysplastic syndromes (MDS). Impaired immune‐regulation, preferentially affecting cytotoxic T cells (CTL), has been largely observed in MDS. Recently, we described the TR3−56 T cell subset, characterised by the co‐expression of CD3 and CD56, as a novel immune‐regulatory population, able to modulate cytotoxic functions. Here, we address the involvement of TR3−56 cells in MDS pathogenesis/progression. Objectives: To analyse the relationship between TR3−56 and CTL activation/expansion in bone marrow (BM) of very‐low/low‐risk MDS subjects. Methods: Peripheral blood and BM specimens, obtained at disease onset in a cohort of 58 subjects, were analysed by immune‐fluorescence and flow cytometry, to preserve the complexity of the biological sample. Results: We observed that a trend‐increase of BM TR3−56 in high/very‐high MDS stage, as compared with very‐low/low group, associates with a decreased activation of BM resident CTL; significant correlation of TR3−56 with BM blasts has been also revealed. In addition, in very‐low/low‐risk subjects the TR3−56 amount in BM inversely correlates with the presence of activated BM CTL showing a skewed Vβ T‐cell repertoire. Conclusions: These data add TR3−56 to the immune‐regulatory network involved in MDS pathogenesis/progression. Better knowledge of the immune‐mediated processes associated with the disease might improve MDS clinical management.